Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme A reductase-inhibitor therapy

Clinical Therapeutics

Volumn 21, Issue 2, 1999, Pages 422-429

  Strauss, William E ^a,b,c   Alexis, George ^a   Tapley, Ronald D ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug utilization review; HMG CoA reductase inhibitor; Pravastatin; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PRAVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MONITORING; DRUG USE; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION;

EID: 0032942083     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88297-1     Document Type: Article

References (19)

1. 1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. 2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 1996;335:1001-1009.
3. 3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;333:1301-1307.
4. 4. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
5. 5. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Publication no. 93-3095. Bethesda, Md: National Institutes of Health; 1993.
6. 6. Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
7. 7. Pearson TA, Fuster V. The 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Executive summary. J Am Coll Cardiol. 1996;27:961-963.
8. 8. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1959-1968.
9. 9. Cohen MV, Byren M, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
10. 10. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. JAMA. 1993;269:1133-1138.
11. 11. Miller M, Konkel K, Fitzpatrick D, et al. Divergent reporting of coronary risk factors before coronary artery bypass surgery. Am J Cardiol. 1995;75:736-737.
12. 12. Giugliano RP, Camargo CA, Lloyd-Jones DM, et al. Prevalence of hypercholesterolemic and lipid management in patients presenting with unstable angina. J Am Coll Cardiol. 1996;27:134A. Abstract.
13. 13. Giugliano RP, Camargo CA Jr, Lloyd-Jones RC, et al. Differences in lipid management across the spectrum of acute coronary artery disease. J Am Coll Cardiol. 1977;29:400A. Abstract.
14. 14. O'Mahoney S, Danias PG, Silverman DI, et al. Cholesterol levels are underevaluated and undertested. J Am Coll Cardiol. 1997;29:400A. Abstract.
15. 15. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
16. 16. Schrott HG, Bittner V, Vittinghoff E, et al, tor the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. JAMA. 1997;277:1281-1286.
17. 17. Pearson TA, Laurora IM. Attainment of LDL-cholesterol goals in a national sample: Results from the Lipid Treatment Assessment Project. J Am Coll Cardiol. 1998;31:88A. Abstract.
18. 18. Miller M, Byington RP, Hunninghake D, et al. Lipid lowering therapy in CAD patients at academic medical centers: Undertreatment and evidence of a gender gap. J Am Coll Cardiol. 1998;31:186A. Abstract.
19. 19. Marcellino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.